Quality standard

Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour

Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour

Quality statement

Adults who are having transurethral resection of bladder tumour (TURBT) have detrusor muscle obtained during the procedure.

Rationale

Obtaining detrusor muscle during TURBT is important for assessing the stage and type of bladder cancer, which can help to identify the most effective treatment.

Quality measures

The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.

Structure

Evidence of local arrangements to ensure that adults having TURBT have detrusor muscle obtained during the procedure.

Data source: Local data collection.

Process

Proportion of TURBT procedures during which detrusor muscle was obtained.

Numerator – the number in the denominator in which detrusor muscle was taken at the time of performing the TURBT.

Denominator – the number of TURBT procedures performed.

Data source: Local data collection.

What the quality statement means for different audiences

Service providers (secondary care services) ensure that systems are in place for adults who are having TURBT to have detrusor muscle obtained during the procedure.

Healthcare professionals ensure that adults who are having TURBT have detrusor muscle obtained during the procedure.

Commissioners ensure that they commission services that obtain detrusor muscle during TURBT procedures.

Adults who are having an operation to take tissue samples to check for bladder cancer (called transurethral resection of bladder tumour, or TURBT for short) have samples taken that include tissue from the muscle wall of their bladder. If cancer is found in their bladder, the type of treatment will depend on whether or not the cancer has grown into the muscle wall.

Source guidance

Bladder cancer. NICE guideline NG2 (2015), recommendation 1.2.4